Pharma Stocks Bond – available on secondary market

Opportunity for an annual interest rate of 4% with 100% capital protection at the end of the term and an 8 year term

The Pharma Stocks Bond is a Guarantee Certificate based on three international blue chips of the pharmaceutical industry (AstraZeneca PLC, Novartis AG, Sanofi SA) with full capital protection at the end of the term. The certificate is suitable for security-oriented investors, who want to make a medium/long-term investment in these pharma stocks and who expect stable stock price developments in the pharmaceutical industry.

Payout profile:

The Guarantee Certificate combines the opportunity for an annual interest rate of 4% with 100% capital protection for the invested capital. The annual interest rate is paid out, provided that each of the three underlying shares quotes AT or ABOVE its respective starting value (=closing price of each share at the initial valuation date) at the annual valuation date.

In case the closing price of one or more underlying shares quotes below the respective starting value at the respective annual valuation date, the interest payment does not apply for the respective year. However, investors have the opportunity to obtain 4% interest in each of the following years too. This means, investors still have the possibility to profit from positive performances of the blue chips.

At the end of the term the investment is 100% capital protected by Raiffeisen Centrobank, i.e. during the term price fluctuations may occur, but investors obtain at least 100% of the nominal value at the end of the term.

Key Facts:

  • ISIN: AT0000A1N979
  • Initial valuation date: Sep 12, 2016
  • Term: 8 years (maturity date: Sep 16, 2024)
  • Public offer in: Austria, Germany, Italy, Hungary, Poland, Czech Republic, Slovakia, Romania, Slovenia, Croatia
  • Listing: Vienna, Frankfurt, Stuttgart

Further information is available at the product page: Pharma Stocks Bond

For more details kindly see the Product Folder (PDF).

For any additional information you may require do not hesitate to contact us on +43 1 515 20-484.

The Team “Structured Products” of Raiffeisen Centrobank

This product, the risks and terms and conditions associated with it, are subject to and governed by the Prospectus (including all supplements and amendments thereto) approved by the Austrian Financial Market Authority, which has been deposited at Oesterreichische Kontrollbank AG and is published on

Additionally, Raiffeisen Centrobank AG is subject to supervision by the European Central Bank (ECB), which ECB undertakes within the Single Supervisory Mechanism (SSM), which consists of the ECB on national responsible authorities (Council Regulation (EU) No 1024/2013).





Key facts:
  • Name: Pharma-Aktien Bond
  • ISIN: AT0000A1N979
  • Initial valuation date: Sep 12, 2016
  • Term: 2.5 years
    (Maturity date: Sep 16, 2024)
  • Listing: Vienna, Frankfurt, Stuttgart
This is advertising that does not constitute investment advice, an offer, a recommendation or an invitation to submit an offer. Comprehensive information about the financial instrument and its opportunities and risks - see approved (basis) prospectus (including all supplements), published under Additional information also in the Key Information Document and under "Customer Information and Regulatory Issues" at The approval of the prospectus should not be construed as endorsement of this financial instrument by the authority (FMA). You are about to purchase a product that is not simple and difficult to understand. We recommend that you read the prospectus before making an investment decision. The investor bears the credit risk of Raiffeisen Centrobank AG (RCB) when purchasing the financial instrument. The certificate is subject to specific rules that may already be disadvantageous in case of a probable default of RCB (for example, suspension of interest payments) - see Certificates issued by RCB are no financial products as defined in the Regulation (EU) 2019/2088.
The Structured Products Team
T: +43151520484
E: produkte(at)